WATCH TV LIVE

FDA: Remove GLP-1 Drug Suicide Warnings

(Dreamstime)

Tuesday, 13 January 2026 10:00 AM EST

The U.S. Food and Drug Administration on Tuesday ‍requested companies ‍to remove warnings related ⁠to the potential risk of suicidal ideation from the labeling of popular weight-loss drugs of ‍the GLP-1 class.

The action ⁠follows a comprehensive FDA review that found no increased risk of ⁠suicidal ideation ⁠and behavior associated with the ‍use of GLP-1 drugs, ‌which include Novo Nordisk's Wegovy and older ⁠drug Saxenda, ‍and Eli Lilly's Zepbound.

Click Here to comment on this article

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

Yes, Send Me News Alerts via email

(Optional for Local News)

Privacy: We never share your email address.

Join the Newsmax Community

Read and Post Comments
Please review Community Guidelines before posting a comment.

Find Your Condition

Cancer	Heart Disease
Obesity	Arthritis
Alzheimer's/Dementia	Digestive Problems
Cold/Flu	Depression
Allergies	High Cholesterol
Chronic Pain	Thyroid Disorders
Menopause	Osteoporosis
Autism	Anxiety
High Blood Pressure	Diabetes

More Conditions

TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.